Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
Last trade$1.62
Day change+$0.325 (+25.19%)
Day range$1.40 – $1.73
Volume8,530,379
Market cap$122M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for GLAS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for GLAS.
Recent news
Company coverage with links to the original publishers.
InspireMD (NSPR) beat earnings expectations with a loss of $0.11 per share versus consensus estimate of $0.15, representing a 26.67% earnings surprise. The company also surpassed revenue estimates at $2.24 million. However, shares have declined 55.1% year-to-date, significantly underperforming the S&P 500's 11.3% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Glass House Brands Inc. replaced auditor BDO with MGO effective November 6, 2026, citing BDO's inability to complete Q3 review procedures by the November 16 reporting deadline. BDO had not finished evaluating the accounting for the company's deconsolidation transaction and characterized the incomplete review as a reportable event, which Glass House disputes.
Exagen Inc. (XGN) reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.19, representing a -31.58% earnings surprise. Revenue of $18.42 million slightly exceeded expectations by 0.73%. The stock has outperformed the S&P 500 by 6.5% year-to-date, but the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Products industry ranks in the bottom 40% of Zacks industries.
Haemonetics (HAE) reported quarterly earnings of $1.35 per share, beating consensus estimates of $1.30, with revenues of $357.76 million exceeding expectations by 3.15%. The company has outperformed market estimates in four consecutive quarters and gained 59% year-to-date. However, the Medical-Products industry ranks in the bottom 36% of Zacks industries, which could limit future performance despite HAE's Zacks Rank #2 (Buy) rating.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.